856256-49-0

Basic information

• Product Name: 1,4,5,6-Tetrahydro-6-methyl-3-cyclopentapyrazolecarboxylic acid
• Synonyms: 1,4,5,6-Tetrahydro-6-methyl-3-cyclopentapyrazolecarboxylic acid;6-Methyl-1,4,5,6-tetrahydrocyclopentapyrazole-3-carboxylic acid;6-Methyl-1,4,5,6-Tetrahydrocyclopenta[C]Pyrazole-3-Carboxylic Acid;6-Methyl-1,4,5,6-Tetrahydrocyclopenta[C]Pyrazole-3-Carboxylic Acid(WX614099)
• CAS NO: 856256-49-0
• Molecular Formula: C8H10N2O2
• Molecular Weight: 166.1772
• Mol File: 856256-49-0.mol

Chemical Properties

• Boiling Point: 392.649°C at 760 mmHg
• Flash Point: 191.267°C
• Appearance: /
• Density: 1.355±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.612
• CAS DataBase Reference: 1,4,5,6-Tetrahydro-6-methyl-3-cyclopentapyrazolecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4,5,6-Tetrahydro-6-methyl-3-cyclopentapyrazolecarboxylic acid(856256-49-0)
• EPA Substance Registry System: 1,4,5,6-Tetrahydro-6-methyl-3-cyclopentapyrazolecarboxylic acid(856256-49-0)

Safety Data

• Hazardous Substances Data: 856256-49-0(Hazardous Substances Data)

Usage

Derivative of

Pyrazole

Classification

Carboxylic acid

Potential pharmacological activity

Yes

Studied for

Development of new drugs

Used as

Building block in the synthesis of other organic compounds

Structure

Distinct and versatile

Field of application

Organic chemistry and pharmaceutical research

InChI:InChI=1/C8H10N2O2/c1-4-2-3-5-6(4)9-10-7(5)8(11)12/h4H,2-3H2,1H3,(H,9,10)(H,11,12)

Relevant articles and documents

3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice

The discovery and profiling of 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro- cyclopentapyrazole (5a, MK-0354), a partial agonist of GPR109a, is described. Compound 5a retained the plasma free fatty acid lowering effects in mice associated with GPR109a agonism,

Pyrrole and pyrazole DAAO inhibitors

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R1 and R2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR5; or R1 and R2, taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR6R7)n; R3 is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR4; R4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR5; R5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R6 and R7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R1, R2 and R4 is other than hydrogen; and at least one of X and Y is (CR6R7)n. D-serine or cycloserine may be coadministered along with the compound of formula I.